Cholesterol fears rock Immunovant
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Merck KGaA’s dual immuno-oncology weapon misfires
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Mapping the transatlantic divide for biotech flotations
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
J&J snags novel autoimmune project, and Momenta
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
